PDF下载 ( 114 KB)
Diagnostic value of AST/PLT and GGT/PLT for hepatic fibrosis.
-
摘要: 目的探讨AST/PLT和GGT/PLT比值对肝纤维化的诊断价值。方法比较慢乙肝组和正常对照组,不同炎症分级(G)和纤维化程度分期(S)的慢乙肝病例组间血常规、肝功能和血清肝纤维化常规四项指标(HA、CⅣ、PCⅢ和LN)的差异。结果不同程度的S1~4和G1~4的AST/PLT、GGT/PLT、HA、CⅣ、PCⅢ和LN 6项指标与正常人比较,差异均非常显著(P<0.001)。AST/PLT和GGT/PLT比值的阳性率在不同程度的S和G之间均无显著性差异。肝纤维化常规四项指标中阳性率以HA为佳,与前两比值之间无显著差异。结论AST/PLT和GGT/PLT对肝纤维化的诊断有一定价值,但需排除其他原因引起AST、GGT增高和PLT(血小板计数)减少。Abstract: Objective To evaluate diagnostic value of the ratio of AST and PLT (AST/PLT) , the ratio of GGT and PLT (GGT/PLT) for hepatic fibrosis.Methods Comparing blood routine index, hepatic function index and four hepatic fibrosis routine index (HA, CⅣ, PCⅢ and LN) level in the chronic hepatitis B with them in the healthy subjects.Comparing with them in the different division of inflammation grade (G) and the different fibrosis stage (S) of the chronic hepatitis B.Results The serum level of AST/PLT, GGT/PLT, HA, CⅣ, PCⅢ and LN in patients whatever the division of inflammation grade and fibrosis stage were significantly higher than those in the healthy subjects (P<0.01) .However, there was not a statistically significant difference comparing the positive percent of ASP/PLT and GGT/PLT in patients with those in the control group.HA was better than other three indices, its positive percent was not a statistically significant difference as compared with the positive percent of ASP/PLT and GGT/PLT in patients with those in the control group.HA was better than other three indices, its positive percent was not a statistically significant difference as compared with the positive percent of ASP/PLT and GGT/PLT.Conclusion Serum level of AST/PLT and GGT/PLT can be used as the indices for diagnosis of hepatic fibrosis, but the precondition is excluding the possibility of other reasons induce to the heighten of AST or GGT and the dropping of PLT.
-
Key words:
- chronic hepatitis B /
- hepatic fibrosis
-
[1]Gressner AM, Weiskirchen R.Modern pathogenetic concepts of liverfibrosis suggest stellate cell and TGFβ1as major players and thera-peutic targets[J].J cell Mol Med, 2006, 10 (1) ∶76-99. [2]蔡卫民.肝纤维化研究若干进展[J].临床肝胆病杂志, 2006, 22 (3) ∶167-170. [3]Friedman SL, Bansal MB.Reveal of hepatic fibrosis-fact or Fantasy[J]?Hepatology, 2006, 43∶S82-S88. [4]Ghang MG, Doo E.Assessment of liver fibrosis:Palpate, poke ofpulse[J]?Hepatology, 2005, 42 (4) ∶759-762. [5]蔡卫民, 郑敏, 翁红雷, 等.慢性肝炎患者血清纤维化指标的检测及其临床意义[J].中华内科杂志, 2001, 40 (7) ∶448-451. [6]蔡卫民, 陶君, 翁红雷, 等.血清纤维化指标影响因素分析[J].中华肝胆病杂志, 2003, 11 (1) ∶22-25. [7]ZHANG Bin-bin, CAI Wei-min, WENG Hong-lei, et al.Diag-nostic value of PDGF-BB, TGFβ1, MMP-1 and TINP-1 in ser-um and PBMCs for hepatic fibrosis[J].Word J Gastroenterol, 2003, 9 (11) ∶2490-2496. [8]Wai CT, Greenson JK, Fontana BJ, et al.A simple noninvasive in-dex can predict both significant fibrosis and cirrhosis in patients withchronic hepatitis[J].Hepatology, 2003, 38 (2) ∶518-526. [9]Cales P, Oberti F, Michalat S, et al.Anovel panel of blood markersto assess the degree of liver fibrosis[J].Hepatology, 2005, 42 (6) ∶1373-1381. [10]张文胜, 王宝恩, 王泰龄, 等.慢性乙型肝炎肝纤维化无创性诊断模型的建立[J].中华肝脏病杂志, 2006, 14 (3) ∶169-173. [11] 蔡卫民, 孙永良, 张立煌, 等.肝纤维化血清诊断的初步探讨-附612例慢性肝病患者11次血清结果分析[J].中西医结合肝病杂志, 1999, 5 (1) ∶3-6. -
本文二维码
计量
- 文章访问数: 2505
- HTML全文浏览量: 27
- PDF下载量: 989
- 被引次数: 0
下载:
